



Development of a model of focal pneumococcal pneumonia in young rats

Citation

Malley, Richard, Anne M. Stack, Robert N. Husson, Claudette M. Thompson, Gary R. Fleisher, and Richard A. Saladino. 2004. Development of a model of focal pneumococcal pneumonia in young rats. *Journal of Immune Based Therapies and Vaccines* 2: 2.

Published Version

doi:10.1186/1476-8518-2-2

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:4874841>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Original research

Open Access

Development of a model of focal pneumococcal pneumonia in young rats

Richard Malley*^{1,2}, Anne M Stack¹, Robert N Husson²,
Claudette M Thompson³, Gary R Fleisher¹ and Richard A Saladino^{1,4}

Address: ¹Division of Emergency Medicine, Children's Hospital, Harvard Medical School, Boston MA, USA, ²Division of Infectious Diseases, Children's Hospital, Harvard Medical School, Boston MA, USA, ³Harvard School of Public Health, Boston MA, USA and ⁴Division of Pediatric Emergency Medicine, Department of Pediatrics, Children's Hospital, Pittsburgh PA, USA

Email: Richard Malley* - richard.malley@childrens.harvard.edu; Anne M Stack - anne.stack@childrens.harvard.edu; Robert N Husson - robert.husson@childrens.harvard.edu; Claudette M Thompson - cthomps@hsph.harvard.edu; Gary R Fleisher - gary.fleisher@childrens.harvard.edu; Richard A Saladino - saladir@chplink.chp.edu

* Corresponding author

Published: 23 January 2004

Received: 02 December 2003

Journal of Immune Based Therapies and Vaccines 2004, 2:2

Accepted: 23 January 2004

This article is available from: <http://www.jibtherapies.com/content/2/1/2>

© 2004 Malley et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: A recently licensed pneumococcal conjugate vaccine has been shown to be highly effective in the prevention of bacteremia in immunized children but the degree of protection against pneumonia has been difficult to determine.

Methods: We sought to develop a model of *Streptococcus pneumoniae* pneumonia in Sprague-Dawley rats. We challenged three-week old Sprague-Dawley pups via intrapulmonary injection of *S. pneumoniae* serotypes 3 and 6B. Outcomes included bacteremia, mortality as well histologic sections of the lungs.

Results: Pneumonia was reliably produced in animals receiving either 10 or 100 cfu of type 3 pneumococci, with 30% and 50% mortality respectively. Similarly, with type 6B, the likelihood of pneumonia increased with the inoculum, as did the mortality rate. Prophylactic administration of a preparation of high-titered anticapsular antibody prevented the development of type 3 pneumonia and death.

Conclusion: We propose that this model may be useful for the evaluation of vaccines for the prevention of pneumococcal pneumonia.

Background

Streptococcus pneumoniae is the leading cause of bacterial pneumonia in children and adults in both developing and developed countries. In the United States, *S. pneumoniae* accounts for about 500,000 cases of pneumonia each year [1]. The recent dramatic rise in the prevalence of clinical isolates that are multi-drug resistant raises the possibility that antibiotic therapy may become less effective in treating pneumococcal disease. At the same time, the institu-

tion of universal immunization with polysaccharide-protein conjugates in the United States offers the promise of significant reduction in the number of cases of invasive pneumococcal disease [2]. The extent to which conjugate vaccines will have an impact on mucosal and respiratory pneumococcal disease, however, is less certain. Data from the Kaiser Permanente Northern California vaccine trials and phase IV studies suggest a significant reduction in the frequency of clinically-diagnosed as well as radiologically-

confirmed pneumonia [2,3]. Due to the difficulties inherent in the diagnosis of pneumonia, however, these data must be interpreted with caution.

In addition, because the distribution of serotypes responsible for pneumococcal pneumonia is not as well characterized as for bacteremic disease, the spectrum of coverage provided by conjugate vaccines may be narrower for non-bacteremic pneumonia than for bacteremic illness. This is particularly relevant in the developing world, where pneumococcal serotypes responsible for both invasive and mucosal disease differs from that in industrialized countries [4].

Current animal models of pneumococcal disease have several limitations. Not all serotypes are reliably pathogenic in mice and most models require very high inocula to cause disease. In addition, existing animal models of invasive pneumococcal disease are highly virulent and depend on outcomes such as bacteremia, sepsis and mortality [5-8]. These models, with the exception of the chinchilla otitis media model [9], therefore may not be appropriate for the evaluation of vaccines for the prevention of nonbacteremic or mucosal pneumococcal disease.

In this study we sought to develop a model of focal pneumococcal pneumonia in young rats. In addition, we hypothesized that pretreatment with anticapsular pneumococcal antibody would prevent pulmonary pathology in this model.

Methods

Bacteriologic methods

Strains of *Streptococcus pneumoniae* were originally obtained from the collections of Drs. George Siber (Wyeth-Lederle Vaccine and Pediatrics, Pearl River, NY) and David Briles (University of Alabama, Birmingham) and passaged through rats via intraperitoneal challenge as described previously [7]. Passaged strains were stored in either skim milk or Todd-Hewitt broth supplemented with 0.5% yeast extract (Difco Laboratories, Detroit, MI) and 20% glycerol at -70°C, and fresh subcultures were used for all experiments. Inocula for animal challenge were prepared by growing *Streptococcus pneumoniae* to mid-log phase (approximately 10⁷ CFU/ml) in 10 ml of Todd-Hewitt broth supplemented with 0.5% yeast extract. The suspension was diluted in 0.5% low melting-point agarose (as an adjuvant [7]) to a desired inoculum concentration. The number of cfus delivered in the inoculation was calculated the following day based on the dilutions made from the mid-log phase culture.

Animal model

Outbred virus-free Sprague-Dawley rats were obtained from Charles River Laboratories, Wilmington, MA. Preg-

nant female rats were quarantined 4 to 5 days prior to delivery of a litter. On day 4 post delivery, infant pups from all litters were randomly redistributed so that each mother had 10–12 pups. Animals weaned at about three weeks of life, after which the dam was removed and the litter rats were distributed in cages of six animals each.

Intrathoracic inoculations were performed in the following fashion. The right chest of each 3-week-old rat was prepared with alcohol, and a 0.05 ml inoculum was injected transthoracically into the mid-right lung via a 29-gauge needle on an insulin syringe. The depth of the intrathoracic injection was controlled by a small hemostat clipped at the base of the needle. Following the injection, animals were observed for the presence of any distress that may signify the development of a pneumothorax. Animals that appeared ill immediately after the injection were sacrificed.

In a second series of experiments, animals were randomly assigned to receive either 1 cc of bacterial polysaccharide immune globulin (BPIG) or normal saline intraperitoneally, administered 24 hours prior to bacterial challenge. BPIG is a hyperimmune serum obtained from adults immunized with 23-valent pneumococcal vaccine, *Haemophilus influenzae* type b conjugate vaccine and *Neisseria meningitidis* polysaccharide vaccine and consists predominantly of IgG, with trace amounts of IgA and IgM. Outcomes following intrathoracic injection were compared between the two groups (see below).

Outcomes

Mortality was assessed for 7 days after inoculation. Bacteremia was assessed on days 1 and 4 after inoculation. The distal dorsal tail vein of each unanesthetized pup was cleansed with 70% alcohol and punctured with a sterile lancet and 0.01 ml of blood was spread on 5% sheep's blood agar. Plates were incubated overnight at 37°C, and colonies were counted the following morning. The lower limit of detection of bacteremia was 100 cfu/ml.

Randomly selected animals were sacrificed on days 2 and 4 following challenge for lung culture and assessment of lung histopathology. Lung microbiology and histopathology specimens were obtained from randomly selected animals sacrificed on day 2 and 4 following intrathoracic challenge. Lung cultures were obtained using sterile techniques. Lungs were dissected en bloc from the thorax, transported in sterile vials, and then homogenized using a Tissue Tearor (Biospec Products, Inc., Bartlesville, OK). Lung cultures were performed on blood agar plates supplemented with gentamicin (2.5 mg/L) to suppress the growth of normal oral flora. Lung specimens were also obtained for histologic examination. Formalin (10%) was instilled via tracheal instillation via a 20-gauge

Table 1: Effect of serotype and inoculum size on the occurrence of pneumonia, bacteremia, and mortality following intrathoracic challenge in rats

Serotype	Inoculum (cfu)	N	% pneumonia	% bacteremia	% mortality
19	10 ⁶	10	100	50	50
6B	10 ³	5	40	0	0
	10 ⁴	6	33	0	0
	10 ⁵	6	50	0	0
	10 ⁶	12	75	100	100
3	10	10	100	ND	30
	100	10	100	ND	50

ND: not determined

intravenous catheter immediately upon dissection. An animal was considered as having had pneumonia if any area of polymorphonuclear infiltration or infiltrative consolidation of lung parenchyma was seen under 100X.

Experimental procedures for use with animals were reviewed and approved by the Children's Hospital Animal Care and Use Committee, and were in keeping with the guidelines of the National Institutes of Health.

Results

Virulence is dependent on serotype and inoculum size (Table 1)

In our initial experiments, we used a strain of *S. pneumoniae* serotype 3, which was found to be highly virulent in a previously published infant rat model of invasive pneumococcal disease [7]. An inoculum of 10 or 100 cfu reliably produced pneumonia in 100% of animals. This serotype was highly virulent; death occurred in 3/10 and 5/10 animals, with inocula of 10 and 100 cfu respectively. While we did not assay for bacteremia in this subset of animals, we found in pilot experiments that the presence of bacteremia was a highly reliable predictor of mortality in this model (data not shown).

Given the high virulence of type 3 in this model, we next studied a strain of serotype 6B. The aim of these experiments was to select a strain and inoculum size that would cause pneumonia without bacteremia or death. Using inocula ranging from 10³ to 10⁶ colony-forming units (cfu) per 0.05 cc (the volume of the intrathoracic injection), we then examined the frequency with which pneumonia developed. Table 1 demonstrates that the frequency of pneumonia increases with the inoculum size. This can also be seen with representative histopathological sections in Figure 1. Bacteremia was only detected in animals that received the highest inoculum (10⁶ cfu/dose). Nonbacteremic animals looked clinically well up to seven days after inoculation. This remained true regard-

less of whether pneumonia was present on histopathological examination.

From these experiments, we concluded that a transthoracic inoculum of this strain of serotype 6B with 10⁵ cfu would result in pneumonia in approximately 50% of animals, without causing bacteremia. Using a similar inoculum with a serotype 19F isolate (10⁶ cfu), pneumonia was produced in all challenged animals, but was also associated with 50% bacteremia and mortality.

Pretreatment with bacterial polysaccharide immune globulin prevents pneumonia and death (Table 2)

For the following experiments, animals were challenged intrathoracically with WU-2, a serotype 3 laboratory strain of *S. pneumoniae*. Animals that received prophylactic intraperitoneal administration of 1 ml BPIG were significantly less likely to develop pneumonia than animals that received saline (0/23 vs. 17/30 (57%), $p < 0.0001$). Mortality was significantly reduced as well in pre-treated animals (2/30 vs. 14/30, $p < 0.001$).

Discussion

We have developed a model of focal pneumococcal pneumonia in young rats. As has been previously noted in mouse and infant rat models by different investigators, we found that the virulence of *Streptococcus pneumoniae* in our model is dependent on the serotype. In our model, the bacterial inoculum necessary to produce pneumonia in >50% of animals was 100 cfu for WU-2 (serotype 3 strain) and 10⁵ cfu for a serotype 6B strain, a 1000-fold difference. By varying the serotype and the inoculum, the frequency of pneumonia and the mortality rate was correspondingly modified. Of interest, despite the high virulence of WU-2 in this model, pneumonia and mortality could still be abrogated by pre-administration of bacterial polysaccharide immune globulin.

Previously established animal models of pneumococcal invasive disease have several disadvantages. The most




Figure 1

Hematoxylin-Eosin stain preparation of lung sections (original magnification 100×) obtained from autopsied rats following injection with a low (100 cfu per injection, panel A), medium (1000 cfu per injection, panel B) and high (10,000 cfu per injection, panel C) inoculum of type 6B pneumococcus in 0.5% low melting-point agarose. As the size of the inoculum increases, there is a clear progression from normal-appearing lung, focal pneumonia and diffuse pneumonia. Shown are 3 slides from a representative experiment.

Table 2: Pretreatment with bacterial polysaccharide immune globulin (BPIG) prevents pneumonia and death due to type 3 pneumococcus in rats

Serotype	Inoculum (cfu)	Pretreatment	N	# animals with pneumonia (%)	mortality n, (%)
3	100	Saline	30	17 (57)	14 (47)
	100	BPIG	30	0 (0) *	2 (7) **

* P < 0.0001 and ** P < 0.001 by Fisher's Exact

commonly used model of pneumococcal disease has been the mouse model [5], in which very high inocula are required, particularly for higher numbered serotypes, which are less virulent in the mouse. Furthermore, these models require intraperitoneal or intravenous routes of inoculation, which are not representative of the human route of pulmonary infection. Conversely, we have previously published data from an infant rat model in which inocula of different serotypes ranging from 1 to 400 cfu caused overwhelming pneumonia and sepsis [7]. While this model has been useful for the determination of minimal protective concentrations of anticapsular antibodies (a range that was subsequently confirmed in the Kaiser Permanente heptavalent pneumococcal conjugate trial in California), a legitimate concern is that this model may result in an underestimation of the protective capacity of antibodies (whether capsular or other), by virtue of increased susceptibility of the infant rat to pneumococci. The data presented here may represent a more physiologically relevant model of pneumococcal pneumonia. Using a strain of serotype 6B, we show that at the highest inoculum of 10^6 cfu per injection, animals develop a fulminant pneumonia with 100% bacteremia and mortality. In contrast, lowering the inoculum (using a range between 10^3 and 10^5 cfu per injection), we were able to show that pneumonia can be reproduced reliably, without concomitant bacteremia, sepsis, or high mortality. In sum, we propose that this model may therefore be more applicable for the study of the pathophysiology and therapeutic interventions in nonbacteremic pneumococcal pneumonia than previously published models.

We previously showed that the onset of bacteremia and sepsis occurs later in rats challenged via the intrathoracic route compared to the intraperitoneal route [7]. We also demonstrated that rats challenged via the intrathoracic route reliably develop pneumococcal pneumonia, as demonstrated by an increase in the colony counts from whole lung tissue cultures. Together, these data suggest that the initial event leading to disease in these animals is the establishment of pneumococcal pneumonia, followed by seeding of the bloodstream and subsequent sepsis.

Recent data suggest that the expression of virulence genes is phase-variable [10]. Most recently, investigators have demonstrated that pneumococci grown in peritoneal fluid express significantly more pneumolysin, a known intracellular pulmonary toxin, than those cultured in vitro [11]. It is quite plausible that the expression of different virulence genes may vary depending on whether the organism is grown in the lung versus the bloodstream or peritoneum. Using our model of nonbacteremic pneumococcal pneumonia, an analysis of the virulence genes expressed during lung infection vs. peritoneal challenge may provide important information regarding the pathophysiology of pneumococcal lung disease and the factors which promote dissemination of pneumococci from the lung to the bloodstream.

Conclusions

We have developed a model of nonbacteremic pneumococcal pneumonia in the Sprague-Dawley rat. The inocula in this model range from 10^2 and 10^4 cfu per intrathoracic injection, which are substantially lower than that required in mouse models of pneumococcal disease. We were able to utilize this model to demonstrate a protective effect of anticapsular antibody against pneumonia and death. In this light, we propose that this model may be useful for the evaluation of vaccines for the prevention of pneumonia as well as for the study of the pathophysiologic mechanisms that lead to the development of pneumonia and bacteremia.

Competing interests

None declared.

Authors' contributions

RM, AMS, CMT and RAS carried out the animal experiments, participated in the analysis and all contributed to the original drafts of the manuscript. RM and AMS reviewed the histological preparations. RNH and GRF participated in the design of the study, the interpretation of the results and in the statistical analysis. All authors read and approved the final manuscript.

Acknowledgements

None

References

1. **WHO meeting on maternal and neonatal pneumococcal immunization.** *Wkly Epidemiol Rec* 1998, **73**:187-188.
2. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K: **Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group [In Process Citation].** *Pediatr Infect Dis J* 2000, **19**:187-195.
3. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F: **Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine.** *Pediatr Infect Dis J* 2001, **20**:1105-1107.
4. Hausdorff WP, Bryant J, Paradiso PR, Siber GR: **Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I [In Process Citation].** *Clin Infect Dis* 2000, **30**:100-121.
5. Frimodt-Moller N: **The mouse peritonitis model: present and future use.** *J Antimicrob Chemother* 1993, **31 Suppl D**:55-60.
6. Aaberge IS, Eng J, Lermark G, Lovik M: **Virulence of Streptococcus pneumoniae in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum.** *Microb Pathog* 1995, **18**:141-152.
7. Saladino RA, Stack AM, Fleisher GR, Thompson CM, Briles DE, Kobzik L, Siber GR: **Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant rats.** *Infect Immun* 1997, **65**:4701-4704.
8. Giebink GS, Berzins IK, Quie PG: **Animal models for studying pneumococcal otitis media and pneumococcal vaccine efficacy.** *Ann Otol Rhinol Laryngol Suppl* 1980, **89**:339-343.
9. Giebink GS: **Otitis media: the chinchilla model.** *Microb Drug Resist* 1999, **5**:57-72.
10. Weiser JN, Markiewicz Z, Tuomanen EI, Wani JH: **Relationship between phase variation in colony morphology, intrastrain variation in cell wall physiology, and nasopharyngeal colonization by Streptococcus pneumoniae.** *Infect Immun* 1996, **64**:2240-2245.
11. Orihuela CJ, Janssen R, Robb CW, Watson DA, Niesel DW: **Peritoneal culture alters Streptococcus pneumoniae protein profiles and virulence properties.** *Infect Immun* 2000, **68**:6082-6086.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

